{"meta":{"query_hash":"fe933d0e8be0","filters":{"venue":"Therapeutic Advances in Hematology"},"cohort_total":20,"direct_labels_cover":0,"predictions_cover":20,"exported":20,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/fe933d0e8be0","api":"https://metacan.xera.ac/api/v1/cohort?venue=Therapeutic+Advances+in+Hematology"},"results":[{"id":"W2102216347","doi":"10.1177/2040620712453067","title":"Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism","year":2012,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Hamilton General Hospital","funders":"Bayer HealthCare","keywords":"Medicine; Rivaroxaban; Dabigatran; Apixaban; Edoxaban; Deep vein; Pulmonary embolism; Atrial fibrillation; Thrombosis; Intensive care medicine; Warfarin; Surgery; Internal medicine","score_opus":0.030524975829067942,"score_gpt":0.3507486128392116,"score_spread":0.32022363701014367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102216347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9189786,0.078600585,0.0001228304,0.00049692433,0.00007263336,0.001098429,0.00000172672,0.0000058445676,0.00062245777],"genre_scores_gemma":[0.92548156,0.07419055,0.00017271111,0.000051888743,0.000019782634,0.00006349016,0.0000061455075,0.000008483737,0.000005396445],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988167,0.00022615198,0.00044035277,0.00017212142,0.000106663814,0.00023798598],"domain_scores_gemma":[0.99912614,0.00043706375,0.00017281476,0.00022876935,0.000012712498,0.000022492157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029252766,0.00015702171,0.000717829,0.00012893851,0.000033330656,0.000002933327,0.000060997947,0.000059426755,0.000011819507],"category_scores_gemma":[0.000016549095,0.0000857709,0.000043030333,0.00020774345,0.00024838053,0.00019824541,0.000018740702,0.00005341134,4.8360255e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000472458,0.0034924436,0.4363862,0.00017975675,0.00007704492,0.000005510743,0.013200385,0.0001229784,0.00013258462,0.06332683,4.5896226e-7,0.48260334],"study_design_scores_gemma":[0.0052285846,0.0012934761,0.978981,0.00019262674,0.00021252928,0.00005178757,0.0021087634,0.00019766483,0.000851502,0.006661616,0.0041151047,0.00010533495],"about_ca_topic_score_codex":0.000096500444,"about_ca_topic_score_gemma":0.00050407066,"teacher_disagreement_score":0.5425948,"about_ca_system_score_codex":0.000055021457,"about_ca_system_score_gemma":0.000015951437,"threshold_uncertainty_score":0.34976357},"labels":[],"label_agreement":null},{"id":"W2122059243","doi":"10.1177/2040620715571077","title":"Targeting polo-like kinase 1 in acute myeloid leukemia","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"PLK1; Medicine; Cytarabine; Myeloid leukemia; Leukemia; Polo-like kinase; Myeloid; Clinical trial; Oncology; Cancer research; Internal medicine; Cell cycle; Pharmacology; Cancer","score_opus":0.053688199064231314,"score_gpt":0.4039952893888705,"score_spread":0.3503070903246392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122059243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007103778,0.99436164,0.00015618293,0.00019145283,0.0006440155,0.002242541,0.000024596198,0.00012638734,0.0021821747],"genre_scores_gemma":[0.00015012267,0.9955947,0.0018137865,0.00044681,0.00019432296,0.0006243559,0.00026006636,0.00020550474,0.00071035954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99404967,0.00083466346,0.0018092719,0.0011971124,0.00057529646,0.0015339986],"domain_scores_gemma":[0.99700975,0.00089584204,0.0005599509,0.0010675334,0.00015057239,0.00031636292],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013572129,0.0009505922,0.005367553,0.0013033749,0.000059191443,0.00001827818,0.0008415497,0.0011649933,0.0002567104],"category_scores_gemma":[0.00023713615,0.0007650434,0.00036798982,0.0015854301,0.00054350507,0.00025373744,0.0003816352,0.002840116,0.0004153326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000272372,0.00012847884,0.00020855114,0.012123747,0.00025678056,0.0034528642,0.00020419578,0.000011295032,0.0000042008883,0.0014270957,0.00038055461,0.9815299],"study_design_scores_gemma":[0.0021050733,0.00023125872,0.0000034529342,0.006890468,0.00050037116,0.0029907308,0.00016104136,0.00015315932,0.000006204184,0.0016544256,0.9846825,0.00062130735],"about_ca_topic_score_codex":0.000057527945,"about_ca_topic_score_gemma":0.00004963743,"teacher_disagreement_score":0.9843019,"about_ca_system_score_codex":0.0037601346,"about_ca_system_score_gemma":0.0033872004,"threshold_uncertainty_score":0.99948007},"labels":[],"label_agreement":null},{"id":"W2160410546","doi":"10.1177/2040620712471553","title":"The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Anaplastic lymphoma kinase; Cancer research; Carcinogenesis; Anaplastic large-cell lymphoma; Tyrosine kinase; STAT protein; Signal transduction; STAT3; Biology; Medicine; Lymphoma; Cell biology; Cancer; Pathology; Immunology; Internal medicine; Lung cancer","score_opus":0.01015474149840613,"score_gpt":0.2801749200807791,"score_spread":0.270020178582373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160410546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8884607,0.09808639,0.00007201197,0.010006229,0.00049234455,0.00110621,0.000006482542,0.00003142007,0.0017381986],"genre_scores_gemma":[0.9916842,0.0060244454,0.00019086634,0.001674092,0.000029457455,0.0002595262,0.000004743946,0.000015187407,0.0001174786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998697,0.00017064833,0.00042384458,0.00024023901,0.00011254067,0.00035572692],"domain_scores_gemma":[0.9986301,0.00047757424,0.00018942457,0.0005855711,0.00007077694,0.00004653347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014424698,0.00017335173,0.00045553528,0.00003946297,0.0000971615,0.000006007993,0.0002327322,0.00010349985,0.0001306232],"category_scores_gemma":[0.00005375997,0.00008203227,0.00012324103,0.0002053611,0.0005299303,0.00006248582,0.00008733277,0.00012657915,0.00005920928],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004746912,0.0012237772,0.38969302,0.00013814835,0.00029997967,0.0000828294,0.00046849635,0.000018502373,0.0040941755,0.1560126,0.0003796074,0.44711417],"study_design_scores_gemma":[0.015272591,0.0018262777,0.34056917,0.0005075096,0.0005751075,0.0029876123,0.0009623824,0.0005255663,0.11288083,0.12464311,0.39857757,0.00067226915],"about_ca_topic_score_codex":0.00006548502,"about_ca_topic_score_gemma":0.000102139136,"teacher_disagreement_score":0.4464419,"about_ca_system_score_codex":0.00007034304,"about_ca_system_score_gemma":0.00008474189,"threshold_uncertainty_score":0.3345179},"labels":[],"label_agreement":null},{"id":"W2168385579","doi":"10.1177/2040620715586528","title":"Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Obinutuzumab; Medicine; Rituximab; Fludarabine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Chemotherapy; Cyclophosphamide; Leukemia; Venetoclax; Immunology; Lymphoma","score_opus":0.06151108374895914,"score_gpt":0.40383932520121707,"score_spread":0.34232824145225793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168385579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003033878,0.99206734,0.00008973394,0.000014443375,0.000101958336,0.0071917786,0.000050436163,0.000034318633,0.00014660908],"genre_scores_gemma":[0.0012612257,0.9965869,0.00011926529,0.000023415443,0.00007277459,0.0015749783,0.00008937774,0.0001039372,0.00016812867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718785,0.00023041706,0.0008023535,0.0007231907,0.0003734701,0.00068269216],"domain_scores_gemma":[0.9963374,0.00178498,0.0005101166,0.00086496957,0.00036887976,0.00013361251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023958924,0.00065228564,0.0035030644,0.00023639256,0.000067041,0.0000102589265,0.000278177,0.000371492,0.00003095643],"category_scores_gemma":[0.00006812648,0.00033356066,0.00027500614,0.0005128421,0.0007770278,0.0000837588,0.000059235048,0.00022043691,0.000007972583],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012653458,0.00016523231,0.00003134321,0.027891245,0.0012519239,0.000054658176,0.0007163818,0.000061337596,1.8946196e-8,0.0046281843,0.000010290772,0.96392405],"study_design_scores_gemma":[0.037884373,0.0067856247,0.000005629139,0.010184438,0.004384061,0.00081896794,0.000236274,0.001341279,0.0000045698025,0.0011519899,0.93678015,0.00042262007],"about_ca_topic_score_codex":0.0003293423,"about_ca_topic_score_gemma":0.00024517748,"teacher_disagreement_score":0.9635014,"about_ca_system_score_codex":0.18307987,"about_ca_system_score_gemma":0.045590166,"threshold_uncertainty_score":0.99991167},"labels":[],"label_agreement":null},{"id":"W2756236937","doi":"10.1177/2040620717729128","title":"Red cell genotyping precision medicine: a conference summary","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Blood groups and transfusion","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"NIH Clinical Center; U.S. Department of Health and Human Services; National Institutes of Health; Grifols; Australian Government; Canadian Blood Services","keywords":"Genotyping; Precision medicine; Medicine; Clinical Practice; Medical physics; Family medicine; Pathology; Genotype; Genetics; Biology","score_opus":0.12555192463188275,"score_gpt":0.4248344417129931,"score_spread":0.29928251708111037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756236937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000057213124,0.9825933,0.001007541,0.00023360217,0.00070040824,0.0014118793,0.0000056272243,0.00006435231,0.013977558],"genre_scores_gemma":[0.0006560268,0.99753374,0.00065132324,0.00013580591,0.00018344725,0.0001492882,0.00006700009,0.00007716003,0.0005462079],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99714446,0.00025013988,0.0010691932,0.000753922,0.00027291843,0.0005093938],"domain_scores_gemma":[0.9975101,0.0005693551,0.00061344216,0.0010974591,0.0000819232,0.00012774859],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003785516,0.0005721368,0.0038222633,0.00035782196,0.0001288091,0.000011589388,0.00051236147,0.00068359944,0.0002665684],"category_scores_gemma":[0.00006931606,0.00039501424,0.00028482598,0.00020035148,0.00041230227,0.0001411832,0.000095829375,0.0009335855,0.000051161373],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009845969,0.00011123139,0.00002865987,0.019154314,0.00006239369,0.00025138396,0.000110358545,2.4529993e-7,0.0000023602902,0.0016351762,0.000023262694,0.9785222],"study_design_scores_gemma":[0.0013615217,0.0002787113,0.0000063435878,0.04043603,0.00096861186,0.0013692895,0.000027196334,0.000023122275,0.000006429977,0.0032604705,0.95193636,0.0003259271],"about_ca_topic_score_codex":0.000015777168,"about_ca_topic_score_gemma":0.00003800197,"teacher_disagreement_score":0.9781962,"about_ca_system_score_codex":0.000074284384,"about_ca_system_score_gemma":0.00028211562,"threshold_uncertainty_score":0.99985015},"labels":[],"label_agreement":null},{"id":"W3034142645","doi":"10.1177/2040620720914490","title":"PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Context (archaeology); Oncology; Hodgkin lymphoma; Interim; Regimen; Lymphoma; Internal medicine; Radiation therapy; Clinical trial; Toxicity; Stage (stratigraphy); Medical physics","score_opus":0.15720279791341157,"score_gpt":0.369600646188655,"score_spread":0.21239784827524344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034142645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003935805,0.98991823,0.0006897453,0.0009098067,0.00034960508,0.0066478816,0.00005660804,0.00014360319,0.001245172],"genre_scores_gemma":[0.000420688,0.9819908,0.008818825,0.0015524898,0.00014812393,0.0065165684,0.00029293873,0.00016467828,0.00009486686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965652,0.0002053188,0.0010807321,0.001160571,0.00026288783,0.0007252903],"domain_scores_gemma":[0.99751526,0.0010181137,0.0004244985,0.000737224,0.000047371406,0.00025754588],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001713839,0.0008998202,0.0049153557,0.00033471952,0.000074110874,0.000016342363,0.00038187343,0.00031509082,0.000041828625],"category_scores_gemma":[0.00005647408,0.00065520767,0.00069402833,0.00060519495,0.00012993022,0.00010803956,0.00009123239,0.00018948385,0.00008509144],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000777168,0.00080460403,0.000051443505,0.00817229,0.00048019603,0.00029738405,0.00010011932,0.0000026246266,4.801693e-7,0.0067277574,0.00004033949,0.9825456],"study_design_scores_gemma":[0.0053542573,0.0012556203,0.000031732106,0.0043923035,0.0006288972,0.001258674,0.000040045994,0.000013854665,0.000031755495,0.0010724204,0.9853629,0.0005575519],"about_ca_topic_score_codex":0.0000026994917,"about_ca_topic_score_gemma":0.0000075207854,"teacher_disagreement_score":0.98532254,"about_ca_system_score_codex":0.00062589627,"about_ca_system_score_gemma":0.0006365341,"threshold_uncertainty_score":0.9995899},"labels":[],"label_agreement":null},{"id":"W3094234317","doi":"10.1177/2040620720966137","title":"One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Hematology Association; Alexion Pharmaceuticals","keywords":"Eculizumab; Paroxysmal nocturnal hemoglobinuria; Medicine; Internal medicine; Immunology; Antibody; Complement system","score_opus":0.03983949947990802,"score_gpt":0.32467929945707896,"score_spread":0.28483979997717096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094234317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729367,0.020301951,0.0003149402,0.00056079205,0.00012524259,0.005639825,0.000027779623,0.00001993094,0.00007286883],"genre_scores_gemma":[0.998458,0.00041155916,0.0006042612,0.00022801533,0.000010479155,0.00024328163,0.000018228091,0.000022282626,0.0000038842786],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964893,0.0012193221,0.0012798437,0.0005465018,0.00010592708,0.00035912296],"domain_scores_gemma":[0.99808747,0.00092454103,0.0004871769,0.00034528793,0.000106639476,0.000048864833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061846414,0.0002825956,0.0019109868,0.00016392156,0.000051963896,0.0000067722435,0.00044677008,0.00008835919,0.0002082847],"category_scores_gemma":[0.00011367656,0.00022202652,0.000045224202,0.0003251108,0.00036925395,0.00011147374,0.00029308585,0.00019783872,0.000007400053],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8921115,0.0049907374,0.05544725,0.00048325592,0.0007690442,0.000026674645,0.015329128,0.00014712795,0.011634152,0.0043906914,0.000029316943,0.014641125],"study_design_scores_gemma":[0.9446072,0.008724972,0.0197589,0.0015966136,0.00018132618,0.00006393109,0.009523218,0.00007882699,0.012949099,0.0009306333,0.0009707226,0.0006145604],"about_ca_topic_score_codex":0.00009337511,"about_ca_topic_score_gemma":0.00022900975,"teacher_disagreement_score":0.052495703,"about_ca_system_score_codex":0.000037451446,"about_ca_system_score_gemma":0.00007678978,"threshold_uncertainty_score":0.90539783},"labels":[],"label_agreement":null},{"id":"W3094556560","doi":"10.1177/2040620720966888","title":"Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities—a practical review","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Haemophilia; Dosing; Clotting factor; Haemophilia A; Intensive care medicine; Trough level; Population; Pharmacokinetics; Surgery; Internal medicine","score_opus":0.1926136747927358,"score_gpt":0.5560222201151694,"score_spread":0.3634085453224336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094556560","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000036971016,0.9760145,0.00005319526,0.018916136,0.00021258014,0.0031089312,0.000014710541,0.000034205255,0.0016420344],"genre_scores_gemma":[0.00003425268,0.9934526,0.0028147907,0.0026617148,0.0002406948,0.00038859932,0.00012202029,0.00006066671,0.00022468127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950357,0.0014002837,0.0018710006,0.00077666744,0.00041696063,0.0004993823],"domain_scores_gemma":[0.9942497,0.0045438474,0.00045808408,0.00040619285,0.000111449335,0.00023073266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013353211,0.00048617428,0.0038277889,0.00021945327,0.00003620883,0.000011704629,0.00016652433,0.00045251308,0.00021100508],"category_scores_gemma":[0.0021493605,0.00035419277,0.00026242636,0.0006038653,0.0004299404,0.00021749994,0.00014557742,0.0017325759,0.000091939015],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002214347,0.00057038787,0.0002696075,0.053558767,0.00023305281,0.0024811632,0.0000495132,1.4380642e-7,5.48592e-8,0.0058846623,0.00024295182,0.9364883],"study_design_scores_gemma":[0.0016206474,0.00030107753,0.000008911852,0.021994378,0.0012360696,0.0046059396,0.000040454885,0.00006145454,4.6692864e-7,0.00092542026,0.9689451,0.0002600769],"about_ca_topic_score_codex":0.0000022993224,"about_ca_topic_score_gemma":0.000003246613,"teacher_disagreement_score":0.96870214,"about_ca_system_score_codex":0.0001516549,"about_ca_system_score_gemma":0.00089339714,"threshold_uncertainty_score":0.999891},"labels":[],"label_agreement":null},{"id":"W3112714545","doi":"10.1177/2040620720977039","title":"Adverse events in second- and third-line treatments for acute and chronic graft- <i>versus</i> -host disease: systematic review","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Extracorporeal Photopheresis; Graft-versus-host disease; Adverse effect; Internal medicine; Incidence (geometry); Hematopoietic stem cell transplantation; Population; Disease; Immunology","score_opus":0.0370342065950142,"score_gpt":0.3841141538634325,"score_spread":0.3470799472684183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112714545","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033963035,0.9894933,0.0002310757,0.00018112281,0.00020766472,0.009625752,0.00013080222,0.000042776686,0.000053523258],"genre_scores_gemma":[0.00015669115,0.99623334,0.00027187172,0.0003106419,0.000032791555,0.002539469,0.0002805823,0.00008144401,0.000093189396],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9967875,0.0003451962,0.0014694496,0.0007570026,0.00020205797,0.00043879892],"domain_scores_gemma":[0.99768794,0.0010792592,0.000552983,0.0004390736,0.000033679316,0.00020707134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028415764,0.00064417935,0.004985624,0.00021159835,0.000039166225,0.0000030708175,0.00016345803,0.00025731194,0.0000321951],"category_scores_gemma":[0.00007357197,0.0004886842,0.0002603233,0.0003381559,0.00012580803,0.00013329109,0.0000418578,0.00031787666,0.000018647821],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026378405,0.00009322541,0.000067039764,0.9830615,0.0008140676,0.00026727578,0.00009148213,1.1906022e-7,8.2800716e-7,0.0005335327,0.0000021683932,0.014805006],"study_design_scores_gemma":[0.007095067,0.000623511,0.00001346407,0.90135425,0.026987866,0.0015610777,0.000050220508,0.00006667563,0.0000057221228,0.00037725488,0.06126177,0.0006031311],"about_ca_topic_score_codex":8.6498676e-7,"about_ca_topic_score_gemma":0.000037302256,"teacher_disagreement_score":0.08170723,"about_ca_system_score_codex":0.00025762297,"about_ca_system_score_gemma":0.00029350552,"threshold_uncertainty_score":0.99975646},"labels":[],"label_agreement":null},{"id":"W4226103605","doi":"10.1177/20406207221085202","title":"International consensus recommendations on the management of people with haemophilia B","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Spark Therapeutics; Genentech; Grifols; Swedish Orphan Biovitrum; Baxalta; CSL Behring; Biogen; Novo Nordisk; Sanofi; Chugai Pharmaceutical; McMaster University; Pfizer","keywords":"Haemophilia; Medicine; Haemophilia B; Haemophilia A; Delphi method; Intensive care medicine; Delphi; Pediatrics","score_opus":0.10476563920737725,"score_gpt":0.423291382229807,"score_spread":0.31852574302242975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226103605","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041205443,0.9743575,0.000014243167,0.0039205165,0.00024729903,0.0014232217,0.000023605717,0.000018033561,0.019954383],"genre_scores_gemma":[0.00039737378,0.99736863,0.00053704815,0.00008677502,0.00002199352,0.0006366171,0.00011858501,0.000030184628,0.0008027876],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985047,0.00022197106,0.00045019342,0.0002984424,0.0003003011,0.000224383],"domain_scores_gemma":[0.9982718,0.0010097987,0.00022047931,0.00043696674,0.00002875951,0.000032180007],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025304445,0.00022815248,0.0010035408,0.0002503388,0.00006948953,0.000003702139,0.00028604403,0.000080144535,0.0020443692],"category_scores_gemma":[0.000012090932,0.00012104341,0.00014206278,0.00042106275,0.00018452211,0.000016530239,0.00009666793,0.00044335646,0.000026262995],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015562688,0.00032998584,0.00012319809,0.0044049267,0.00085129007,0.00017926915,0.00009876836,0.0000019288645,2.9640207e-8,0.031487174,0.00007818104,0.96228963],"study_design_scores_gemma":[0.0005743628,0.00024764927,0.000007174479,0.0037265678,0.000383671,0.00049222464,0.00033094676,0.0000073251017,0.0000021224985,0.00072011456,0.99340516,0.00010267256],"about_ca_topic_score_codex":0.000002603536,"about_ca_topic_score_gemma":0.000006143634,"teacher_disagreement_score":0.99332696,"about_ca_system_score_codex":0.00014978452,"about_ca_system_score_gemma":0.00010120989,"threshold_uncertainty_score":0.99886787},"labels":[],"label_agreement":null},{"id":"W4285185611","doi":"10.1177/20406207221091046","title":"The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Paroxysmal nocturnal hemoglobinuria; Eculizumab; Medicine; Complement system; Complement component 5; Immunology; CD59; Complement (music); Internal medicine; Antibody","score_opus":0.05434598404694474,"score_gpt":0.36899612744775684,"score_spread":0.3146501434008121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285185611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007394066,0.99632317,0.000022104468,0.000044476812,0.0009771981,0.0013982689,0.000112897425,0.000023987379,0.00035851137],"genre_scores_gemma":[0.012010222,0.9865545,0.000023743783,0.000051471547,0.000023335873,0.0009523394,0.00028696453,0.000035852398,0.00006159481],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952176,0.0015113226,0.0020035428,0.0005215428,0.000103399354,0.0006425462],"domain_scores_gemma":[0.99632233,0.0017610776,0.0012542057,0.0006203899,0.000023728655,0.000018252282],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007739375,0.00045675252,0.0020180738,0.0002780036,0.00017324279,0.000007605997,0.00057807664,0.00021546666,0.0020019093],"category_scores_gemma":[0.000053358315,0.00033287008,0.0003020347,0.0003949395,0.00048641616,0.00008267189,0.00030899452,0.00070107763,0.000033319153],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029295834,0.0004533464,0.0049056266,0.0076959957,0.00030354806,0.00020761669,0.00023938497,0.000012431097,0.000009779545,0.029741522,0.00019470057,0.9559431],"study_design_scores_gemma":[0.0009193341,0.0001390684,0.00006367449,0.0020765937,0.00014795826,0.0012234029,0.0003348552,0.0000014041053,0.000021361275,0.0033794562,0.9913979,0.0002949659],"about_ca_topic_score_codex":0.000016191536,"about_ca_topic_score_gemma":0.0004861296,"teacher_disagreement_score":0.99120325,"about_ca_system_score_codex":0.00030705176,"about_ca_system_score_gemma":0.00025075956,"threshold_uncertainty_score":0.9999123},"labels":[],"label_agreement":null},{"id":"W4295903721","doi":"10.1177/20406207221118429","title":"Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 <sup>9</sup> /L to &lt;100 × 10 <sup>9</sup> /L) at baseline: the final analysis of EXPAND","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; AOP Orphan; Sierra Oncology; CTI Biopharma; Incyte; FibroGen; Gilead Sciences; BeiGene; Sanofi; MorphoSys; Celgene; AstraZeneca; Novartis; Pfizer; Amgen","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Adverse effect; Internal medicine; Clinical endpoint; Anemia; Phases of clinical research; Gastroenterology; Discontinuation; International Prognostic Scoring System; Clinical trial; Bone marrow; Myelodysplastic syndromes","score_opus":0.013257384808473436,"score_gpt":0.2773913357063457,"score_spread":0.2641339508978723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295903721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319696,0.0046262243,0.000055799104,0.0005415898,0.000016401791,0.0012247754,0.00019880122,0.000012390969,0.00012708272],"genre_scores_gemma":[0.9976799,0.00085202686,0.0004474908,0.00042579323,0.00001173931,0.00031163002,0.0001551063,0.000027553557,0.000088796885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973565,0.00037101278,0.0008302462,0.0005792908,0.00044743047,0.00041551993],"domain_scores_gemma":[0.99745077,0.0015733248,0.00028028272,0.00045282082,0.00012893938,0.000113853544],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045390075,0.00034427765,0.0013527428,0.00045010596,0.00014821593,0.0000069989424,0.00015254066,0.000088696346,0.0010335492],"category_scores_gemma":[0.00008779063,0.00023283839,0.00008634811,0.00090577564,0.00035187832,0.0000825902,0.00017644269,0.00021479369,0.0000030369324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017990177,0.0017379302,0.9229407,0.0002697856,0.0010986137,0.00004851326,0.0051185885,0.027113907,0.00002821303,0.0008638612,0.00004565844,0.022744106],"study_design_scores_gemma":[0.041015144,0.009886449,0.8957158,0.0007160172,0.0025121032,0.00020271032,0.003909707,0.022156896,0.0031344874,0.0003659642,0.01945017,0.00093459024],"about_ca_topic_score_codex":0.000045681303,"about_ca_topic_score_gemma":0.00011472839,"teacher_disagreement_score":0.027224889,"about_ca_system_score_codex":0.00015088361,"about_ca_system_score_gemma":0.00007780828,"threshold_uncertainty_score":0.99987966},"labels":[],"label_agreement":null},{"id":"W4381855175","doi":"10.1177/20406207231177282","title":"Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; National Cancer Institute; Galecto; Incyte; Servier; Celgene","keywords":"Medicine; Myelofibrosis; Essential thrombocythemia; Polycythemia vera; Bone marrow; Internal medicine; Myeloid leukemia; Myeloproliferative neoplasm; Oncology; Population; Myeloid; Acute leukemia; Haematopoiesis; Leukemia; Immunology; Stem cell","score_opus":0.17094447341793698,"score_gpt":0.44510187801768714,"score_spread":0.27415740459975013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381855175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089353486,0.9952183,0.000008945384,0.0005460567,0.0001331734,0.0026875208,0.000036840258,0.00014885652,0.00032678898],"genre_scores_gemma":[0.00096777367,0.9957309,0.00056747627,0.00008028285,0.00010154797,0.0022660014,0.000096792784,0.00012513765,0.00006410274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967388,0.0003725153,0.0009922836,0.0010695452,0.00021199492,0.00061489036],"domain_scores_gemma":[0.99753714,0.0013687016,0.00045608936,0.00035485608,0.00008949718,0.00019371837],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002499624,0.0008592476,0.0037959223,0.00046329424,0.00014028586,0.00003961061,0.000115293136,0.00047773606,0.000036088277],"category_scores_gemma":[0.00008550989,0.0006077031,0.00014479113,0.00043670644,0.00050943927,0.00016860379,0.000119595876,0.0005463269,0.000029599792],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014877749,0.000455922,0.0005999783,0.02110151,0.0006296039,0.0005097332,0.00083289726,2.2605154e-7,1.3347162e-7,0.009505404,0.0000031109264,0.9662127],"study_design_scores_gemma":[0.010496671,0.0034327435,0.00016008464,0.04541438,0.0029795207,0.006226661,0.0012179966,0.0002501434,0.0000562539,0.0030739803,0.9252795,0.0014120605],"about_ca_topic_score_codex":0.0000032412056,"about_ca_topic_score_gemma":0.00009211721,"teacher_disagreement_score":0.96480066,"about_ca_system_score_codex":0.000113979026,"about_ca_system_score_gemma":0.00021196855,"threshold_uncertainty_score":0.9996374},"labels":[],"label_agreement":null},{"id":"W4386205570","doi":"10.1177/20406207231195594","title":"Luspatercept for transfusion-dependent β-thalassemia: time to get real","year":2023,"lang":"en","type":"editorial","venue":"Therapeutic Advances in Hematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"bluebird bio; Ionis Pharmaceuticals; La Jolla Pharmaceutical Company; Alexion Pharmaceuticals; Vertex Pharmaceuticals; Celgene; Sanofi; Amgen; Vifor Pharma; Pfizer; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Thalassemia; Blood transfusion; Intensive care medicine; Internal medicine","score_opus":0.009589591266610426,"score_gpt":0.31268263054642265,"score_spread":0.30309303927981224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386205570","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018921606,0.012432714,0.0016106833,0.0028745031,0.97124237,0.004080356,0.0003091081,0.00054043246,0.005017698],"genre_scores_gemma":[0.004475975,0.20364383,0.0033465412,0.0019853464,0.71717227,0.005197027,0.0043268036,0.0017208614,0.05813133],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99677056,0.00011066979,0.0008322039,0.0008824435,0.0005177573,0.0008863713],"domain_scores_gemma":[0.99710405,0.0017941808,0.00017470363,0.000547214,0.00017403482,0.00020584134],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043210838,0.0005351427,0.0015662359,0.00041020234,0.000092972834,0.0000132106925,0.00033547645,0.0019295034,0.00035376695],"category_scores_gemma":[0.0003251811,0.00045200222,0.0002493836,0.00037091458,0.00014183992,0.00007019655,0.00007656638,0.0010894309,0.00082878233],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004361739,0.0006230588,0.00021074236,0.0029935543,0.00048871187,0.000654568,0.0018529681,0.00027586118,0.00059253856,0.00039494634,0.900616,0.08693529],"study_design_scores_gemma":[0.0033786295,0.00095977203,0.000011671077,0.00074275123,0.00028213294,0.00006143442,0.0002807074,0.0001685361,0.00013862066,0.001840926,0.9916357,0.00049911626],"about_ca_topic_score_codex":0.00006107332,"about_ca_topic_score_gemma":0.00018568194,"teacher_disagreement_score":0.25407004,"about_ca_system_score_codex":0.00022834894,"about_ca_system_score_gemma":0.00035566906,"threshold_uncertainty_score":0.9999492},"labels":[],"label_agreement":null},{"id":"W4391890091","doi":"10.1177/20406207231218624","title":"The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Takeda Pharmaceuticals International; Grifols; Swedish Orphan Biovitrum; Baxalta; CSL Behring; Biogen; Novo Nordisk; Sanofi; Pfizer","keywords":"Medicine; Observational study; Interim analysis; Clinical endpoint; Adverse effect; Quality of life (healthcare); Internal medicine; Clinical trial; Pediatrics; Physical therapy","score_opus":0.016396079128889275,"score_gpt":0.3499241047546473,"score_spread":0.333528025625758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391890091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948958,0.0013707925,0.000015793903,0.0006680041,0.0003510746,0.0019051031,0.0000056423874,0.000008765088,0.0007789926],"genre_scores_gemma":[0.9992844,0.00028882315,0.000024755085,0.000019279438,0.000011797708,0.0001159181,0.000002356328,0.0000136404515,0.00023904319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873984,0.0002541064,0.00030263994,0.00023062273,0.0002847386,0.00018808336],"domain_scores_gemma":[0.9986772,0.0009122737,0.00004715495,0.00025352775,0.00007864594,0.00003119967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048090966,0.000120163735,0.00036945715,0.00016795626,0.00003689641,0.0000049297105,0.0001642765,0.00003835636,0.000013846398],"category_scores_gemma":[0.000058713937,0.000057528745,0.000037230573,0.00047978095,0.00023726943,0.00005591634,0.000088040244,0.00017652988,0.0000019650804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005434992,0.000258967,0.9675235,0.00016219805,0.00015514612,0.000011559915,0.0009428697,0.000009900383,0.000038563423,0.0057275468,0.0000016915684,0.019733045],"study_design_scores_gemma":[0.0062362202,0.00094362185,0.9869265,0.000612544,0.000047969577,0.000006307174,0.00057846506,0.000042526797,0.0011031268,0.0026497657,0.0007786885,0.000074296106],"about_ca_topic_score_codex":0.00004712847,"about_ca_topic_score_gemma":0.0007668645,"teacher_disagreement_score":0.019658748,"about_ca_system_score_codex":0.00007916988,"about_ca_system_score_gemma":0.000065984466,"threshold_uncertainty_score":0.2345954},"labels":[],"label_agreement":null},{"id":"W4402541521","doi":"10.1177/20406207241275376","title":"Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Ipsen; GlaxoSmithKline","keywords":"Medicine; Myeloid; Internal medicine; Oncology","score_opus":0.01123824306989505,"score_gpt":0.32939495014411596,"score_spread":0.3181567070742209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402541521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463296,0.004362959,0.00027789964,0.000051477975,0.00017820174,0.00044937214,0.0000060077773,0.0000037534423,0.00003734259],"genre_scores_gemma":[0.99954003,0.00033946687,0.00005405728,0.00001230569,0.000013407766,0.000014494994,0.000004065505,0.000010694384,0.000011503579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990381,0.00016478695,0.00033469204,0.00025894938,0.00008848176,0.00011500238],"domain_scores_gemma":[0.99952143,0.00007198081,0.00011959807,0.00024296618,0.00002910881,0.000014929844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017699196,0.00010048661,0.00025754128,0.00004741737,0.000020443147,0.0000016335413,0.00009750117,0.00010877686,0.0000035843195],"category_scores_gemma":[0.0000184148,0.000069355134,0.000030070156,0.00018479477,0.00020435413,0.000008613608,0.00008106926,0.0001244976,1.307703e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007014502,0.004313595,0.6214869,0.00020032174,0.00020088999,0.0000027978542,0.0009623952,0.0014603944,0.008342244,0.00061285374,0.0000045606594,0.35539857],"study_design_scores_gemma":[0.041451897,0.029304776,0.8222226,0.00052729953,0.0002603463,0.000049566588,0.0008701295,0.0021484,0.093773,0.0026925215,0.0059505147,0.0007489486],"about_ca_topic_score_codex":0.000011742665,"about_ca_topic_score_gemma":0.00051936856,"teacher_disagreement_score":0.3546496,"about_ca_system_score_codex":0.000012782493,"about_ca_system_score_gemma":0.00005541029,"threshold_uncertainty_score":0.28282204},"labels":[],"label_agreement":null},{"id":"W4405416708","doi":"10.1177/20406207241298088","title":"Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Agios Pharmaceuticals; Vertex Pharmaceuticals; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Blood transfusion; Thalassemia; Internal medicine; Retrospective cohort study; Demographics; Anemia; Hemoglobin; Medical record; Pediatrics; Gastroenterology; Surgery; Demography","score_opus":0.01450649536129391,"score_gpt":0.33640647015400627,"score_spread":0.3218999747927124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405416708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951241,0.0021374843,0.00011413659,0.0004430648,0.00065937475,0.0009539087,0.000010671626,0.00011060501,0.00044662968],"genre_scores_gemma":[0.98444897,0.015098791,0.00005397861,0.00009025799,0.00007703849,0.00008230758,0.000033503125,0.000038721668,0.000076454824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979156,0.00013497213,0.0007106035,0.00060145307,0.0003029542,0.0003343856],"domain_scores_gemma":[0.99898803,0.00036621853,0.000146859,0.00025615914,0.000067793524,0.00017494097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031401686,0.00027494275,0.0008116022,0.0002560849,0.00006365634,0.00001787518,0.00006760413,0.00027522954,0.000116753596],"category_scores_gemma":[0.000040661675,0.00018142378,0.00008385197,0.00032013448,0.00036796462,0.00014362889,0.000028403681,0.0006677359,0.0000071965246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039815958,0.0011982966,0.89070094,0.00009592428,0.0003270403,0.0004704017,0.00030330603,1.9912396e-7,2.148275e-7,0.00037663433,0.00000373029,0.10612515],"study_design_scores_gemma":[0.0028488,0.00258281,0.9915836,0.0004291515,0.0003324304,0.00006615308,0.000556601,0.0001537377,0.0000033448373,0.0002740889,0.000992192,0.00017709885],"about_ca_topic_score_codex":0.00028676388,"about_ca_topic_score_gemma":0.00366578,"teacher_disagreement_score":0.10594806,"about_ca_system_score_codex":0.0001325612,"about_ca_system_score_gemma":0.000092400565,"threshold_uncertainty_score":0.73982465},"labels":[],"label_agreement":null},{"id":"W4412014975","doi":"10.1177/20406207251342199","title":"Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"AOP Orphan; Swedish Orphan Biovitrum; Novartis Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Celgene; Alexion Pharmaceuticals; Ariad Pharmaceuticals; Gilead Sciences; RWTH Aachen University; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Phlebotomy; Internal medicine; Polycythemia vera; Thrombosis; Hematology; Retrospective cohort study; Myelofibrosis; Gastroenterology; Surgery; Bone marrow","score_opus":0.025718908178229527,"score_gpt":0.3605291126465878,"score_spread":0.3348102044683583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412014975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871146,0.00125775,0.00042087716,0.007382772,0.00042827832,0.00313346,0.00015469067,0.00004199068,0.00006555186],"genre_scores_gemma":[0.99408096,0.0004923532,0.002047064,0.00243129,0.000051450057,0.0007591841,0.000026858883,0.000041249878,0.000069616304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962878,0.0006604139,0.0012471935,0.0008747062,0.00042176215,0.0005081185],"domain_scores_gemma":[0.9895106,0.008629901,0.00032081275,0.0011248733,0.0002471432,0.00016669981],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080430706,0.00047922475,0.0015144108,0.00020239768,0.000108735374,0.000013542084,0.00033251394,0.00018039142,0.000061897146],"category_scores_gemma":[0.00085348624,0.0002757427,0.00015591767,0.00059308886,0.00019562677,0.000091782225,0.00013152263,0.00042428283,0.000025160289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20870245,0.0025959713,0.7724775,0.000009043789,0.00085992884,0.000044016717,0.0027540077,0.00009693016,0.0000031713287,0.000116878124,0.000020542835,0.012319564],"study_design_scores_gemma":[0.040305708,0.008209321,0.9470092,0.00022172088,0.00032239896,0.000001752699,0.00093672477,0.000017164719,0.00062941655,0.00031784573,0.0017842875,0.0002444728],"about_ca_topic_score_codex":0.00041713283,"about_ca_topic_score_gemma":0.0016562429,"teacher_disagreement_score":0.17453168,"about_ca_system_score_codex":0.00013767928,"about_ca_system_score_gemma":0.00019971804,"threshold_uncertainty_score":0.9999695},"labels":[],"label_agreement":null},{"id":"W4415458924","doi":"10.1177/20406207251388051","title":"Immunoglobulin treatment and clinical outcomes: data from the Ontario Immunoglobulin Treatment program multicenter case registry","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Ottawa; Sault Area Hospital; Public Health Ontario; University of Toronto; Ottawa Hospital","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Antibody; Clinical trial; Antibody therapy; Health care; Multicenter study; Healthcare system; MEDLINE","score_opus":0.06523791734071023,"score_gpt":0.4231188872636341,"score_spread":0.3578809699229239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415458924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9387807,0.056005448,0.000082012666,0.0020264052,0.00040119587,0.0018705114,0.00008966576,0.00007354188,0.00067049224],"genre_scores_gemma":[0.9827448,0.012079942,0.0026958175,0.00083955034,0.000025595964,0.00025755205,0.0003578012,0.000022528056,0.0009763911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779826,0.00018999893,0.0007553821,0.0007441547,0.00009358579,0.00041862758],"domain_scores_gemma":[0.9970792,0.0010720848,0.0001762148,0.001567545,0.000029322344,0.00007566328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015054007,0.00040491705,0.0010979703,0.000054807002,0.00014326435,0.000028933107,0.00027235612,0.00020822471,0.00009277908],"category_scores_gemma":[0.000050495524,0.00022851201,0.00014887341,0.00013085749,0.00038744105,0.00012904106,0.00015599211,0.0002468693,0.000027120857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011011737,0.0030835392,0.73900956,0.000015085921,0.0014195987,0.0040556667,0.00045456697,0.0000012764933,0.0000012887448,0.0001281804,0.000016190534,0.25071388],"study_design_scores_gemma":[0.059598338,0.004553418,0.49368036,0.0005464794,0.0041210866,0.0075320615,0.0033974673,0.0010365774,0.00011680245,0.004044424,0.42059827,0.0007747205],"about_ca_topic_score_codex":0.021398704,"about_ca_topic_score_gemma":0.11710467,"teacher_disagreement_score":0.4205821,"about_ca_system_score_codex":0.00040542308,"about_ca_system_score_gemma":0.00023956498,"threshold_uncertainty_score":0.9851179},"labels":[],"label_agreement":null},{"id":"W7116052349","doi":"10.1177/20406207251401313","title":"The efficacy and safety of anti-CD20 antibody for the treatment of B-ALL: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Clinical trial; Adverse effect; Antibody; Systematic review; Randomized controlled trial; MEDLINE","score_opus":0.04353487925067105,"score_gpt":0.41296347622671764,"score_spread":0.3694285969760466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116052349","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029189654,0.9788414,0.009284782,0.0049285735,0.000022090268,0.003910001,0.00001472734,0.000007914125,0.00007152535],"genre_scores_gemma":[0.6739624,0.3244609,0.00041632398,0.0005338181,0.0000034110683,0.00041865488,0.0000053171857,0.000010522789,0.0001886283],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9984499,0.00023766431,0.00073894614,0.00022312182,0.00014203526,0.00020828772],"domain_scores_gemma":[0.99153715,0.0075289407,0.00025683932,0.0005443607,0.00010551252,0.000027187796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006292706,0.00016198256,0.002422756,0.00012204569,0.00006771946,0.0000042159227,0.00015166038,0.000054814696,0.000009977991],"category_scores_gemma":[0.00025587092,0.00006722506,0.0002783148,0.0004866478,0.00050990476,0.000026913604,0.000035343208,0.000057848436,2.8655276e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028547589,0.0013703208,0.00444816,0.42324394,0.47056794,0.000029926648,0.0017478965,0.0001382637,0.00040742982,0.08843723,0.000027003976,0.0067271492],"study_design_scores_gemma":[0.0068641733,0.0011109259,0.0009500091,0.0024964241,0.976069,0.00018514264,0.00065187074,0.0043241116,0.0011632656,0.002799115,0.0032011787,0.00018479646],"about_ca_topic_score_codex":0.0000151147615,"about_ca_topic_score_gemma":0.000027545091,"teacher_disagreement_score":0.67104346,"about_ca_system_score_codex":0.00005654473,"about_ca_system_score_gemma":0.00008800146,"threshold_uncertainty_score":0.27413583},"labels":[],"label_agreement":null}]}